This job is no longer available
There are still lots of open positions. Let's find the one that's right for you.
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. Playing a critical role as a lead statistician for oncology clinical studies and the subject matter expert (SME) in Biostatistics within Quantitative Sciences function, this position is to serve as a study-level lead statistician and provide statistical leadership and support for clinical development strategy and programs through product life cycle.
